Syschem India Limited has delivered exceptional financial performance in the nine months of FY25-26, demonstrating strong growth across all key metrics. The pharmaceutical API manufacturer presented comprehensive results showcasing significant improvements in revenue, profitability, and market expansion.

Financial Performance Highlights

The company achieved remarkable growth in 9M FY25-26 compared to the corresponding period in the previous year. Revenue from operations surged by 65%, rising from ₹24,748 lakhs in 9M FY24-25 to ₹40,631 lakhs in 9M FY25-26.

Quarterly Performance Analysis

The third quarter of FY25-26 marked exceptional performance with strong year-on-year improvements. Q3 FY25-26 revenue reached ₹16,164 lakhs compared to ₹9,112.60 lakhs in Q3 FY24-25, representing a 177% increase.

Market Expansion and Sales Performance

Syschem India Limited demonstrated robust performance across both domestic and export markets. Export sales reached ₹107.62 crore in 9M FY25-26, surpassing the full-year FY24-25 exports of ₹90.89 crore. Domestic sales also showed growth, rising to ₹247.83 crore in 9M FY25-26 compared to ₹241.25 crore in FY24-25.

The Q3 performance was particularly strong with export sales surging from ₹26.16 crores in Q3 FY24-25 to ₹53.99 crores in Q3 FY25-26, registering a 106% increase. Domestic sales rose from ₹51.84 crores to ₹87.97 crores, reflecting approximately 70% growth.

Operational Infrastructure and Capacity

The company operates with significant operational capabilities including an installed capacity of approximately 4,200 TPA across a 6-acre land bank area. Syschem serves over 100 consumers and traders globally with 7+ API SKUs and maintains a global footprint across 3 continents and 10+ countries.

Product Portfolio and Market Position

The company manufactures various pharmaceutical APIs including Amoxicillin, Ampicillin, Flucloxacillin, Cloxacillin, Cephalexin, and Cephadroxil. These antibiotics belong to the penicillin and cephalosporin families, serving critical healthcare needs in domestic and international markets.

Corporate Structure and Leadership

Syschem India Limited, incorporated on December 31, 1993, is led by an experienced management team. The shareholding pattern as of December 31, 2025, shows promoter and promoter group holding 56.71% while public shareholding stands at 43.29%. The company is listed on BSE with scrip code 531173 and NSE symbol SYSCHEM, with issued shares of 4,35,13,000.

Syschem India Limited announced exceptional financial results for the quarter ended December 31, 2025, demonstrating remarkable growth across key performance metrics. The pharmaceutical company's Board of Directors approved the unaudited financial results at a meeting held on February 2, 2026, which commenced at 11:00 A.M. and concluded at 3:20 P.M., along with significant expansion plans to capitalize on strong market demand.

Outstanding Q3FY26 Financial Performance

The company delivered impressive quarterly results with substantial year-on-year improvements across all major financial parameters:

The company's revenue growth was driven by strong operational performance, with total income from operations reaching ₹16,164.37 lakhs compared to ₹9,114.22 lakhs in the previous year quarter. Cost management remained effective with total expenses of ₹15,667.85 lakhs, resulting in significantly improved profitability margins.

Strong Nine-Month Performance

For the nine months ended December 31, 2025, Syschem India demonstrated consistent growth momentum:

The nine-month performance showcased the company's ability to maintain growth trajectory throughout the period, with material costs of ₹31,477.08 lakhs and employee benefits expense of ₹708.54 lakhs supporting expanded operations.

Major Plant Expansion Initiative

Responding to tremendous market response for its products, the Board approved a comprehensive expansion of existing manufacturing facilities. The expansion project encompasses multiple strategic components:

The expansion includes addition of new manufacturing units for Amoxicillin and Ampicillin production, along with further expansion of existing CDF units comprising Cloxacillin Sodium, Dicloxacillin Sodium, and Flucloxacillin Sodium. Additionally, the company will expand its Effluent Treatment Plant (ETP) and Multi-Effect Evaporator (MEE) to strengthen environmental compliance and support sustainable operations.

Regulatory Compliance and Corporate Governance

The Board also approved several important corporate governance measures during the meeting. The company adopted a revised Related Party Policy to align with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/P/CIR/2025/135 dated October 13, 2025, subject to Audit Committee approval.

The statutory auditors STAV & CO, Chartered Accountants, conducted a limited review of the financial results and expressed an unmodified conclusion. The financial results were prepared in accordance with Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, and comply with Regulation 33 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Regulatory Intimation and Publication

Following regulatory requirements, the company submitted an intimation under Regulation 47(3) read with Schedule III of SEBI Listing Regulations to BSE Limited on February 3, 2026. The intimation confirmed the publication of Q3FY26 unaudited financial results in newspapers including Jansatta (Hindi) and Financial Express on February 3, 2026, as required by regulatory guidelines.

Strategic Outlook

The approved expansion is expected to significantly enhance Syschem India's manufacturing capacity, operational efficiency, and environmental management capabilities. With the company's strong financial performance providing a solid foundation and the pharmaceutical sector showing robust demand, the expansion positions Syschem India for sustained growth in the coming periods. The December 2026 commissioning timeline indicates the company's commitment to rapid capacity enhancement while maintaining quality standards.